BRNSHIGH SIGNALFINANCIAL10-K

BRNS is experiencing severe financial deterioration with a 66% increase in operating cash burn to $48M, alongside a planned merger with Clywedog that appears to be a distressed combination given the company's weakening position.

The dramatic increase in cash burn rate combined with declining assets suggests BRNS is rapidly consuming its financial resources, making the merger with Clywedog potentially a necessity for survival rather than a strategic choice. The removal of specific product development language and shift in focus to merger-related risks indicates the company may be pivoting away from independent drug development.

Comparing 2026-03-13 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

BRNS shows across-the-board financial deterioration with cash burn accelerating 66% to $48M despite R&D expenses declining 40%, suggesting significant operational inefficiencies or one-time charges. The company's balance sheet contracted substantially with total assets falling 39% to $98M and cash reserves declining 36% to $70.5M, indicating approximately 1.5 years of runway at current burn rates. While the company reduced both current liabilities and R&D spending, the disproportionate increase in operating cash outflows relative to expense reductions signals serious operational challenges that likely necessitated the merger announcement.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-95.9%
$892K→$37K

Capex reduced 95.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
-65.8%
-$28.9M→-$48.0M

Operating cash flow fell 65.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Interest Expense
P&L
+47.4%
$19K→$28K

Interest expense surged 47.4% — significant debt increase or rising rates materially impacting earnings.

Stockholders Equity
Balance Sheet
-42.9%
$130.0M→$74.2M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

R&D Expense
P&L
-39.5%
$42.2M→$25.6M

R&D spending cut 39.5% — could signal cost discipline or concerning reduction in innovation investment.

Total Assets
Balance Sheet
-38.8%
$160.3M→$98.2M

Total assets contracted 38.8% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-38.1%
$125.7M→$77.8M

Current assets declined 38.1% — monitor working capital adequacy and short-term liquidity.

Cash & Equivalents
Balance Sheet
-36.3%
$110.7M→$70.5M

Cash declined 36.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Liabilities
Balance Sheet
-36%
$15.7M→$10.0M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-20.9%
$30.2M→$23.9M

Liabilities reduced 20.9% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-13
PRIOR — 2025-03-20
ADDED
( Clywedog ) contemplated by the Agreement and Plan of Merger (as amended from time to time, the Merger Agreement ), dated September 29, 2025, by and among us, Cdog Merger Sub, Inc.
and Clywedog (the Contemplated Transactions ), and expectations regarding the timing and benefits of, and our ability to consummate, the Contemplated Transactions; the success, cost and timing of our product development activities and clinical trials; the timing, scope or likelihood of regulatory filings and approvals, including timing of Investigational New Drug Application ("IND"), New Drug Application ("NDA"), and Biologics License Application ("BLA") filings for our current and future product candidates, and final U.S.
Food and Drug Administration ("FDA"), European Medicines Agency ("EMA"), U.K.
The failure to successfully integrate our business with that of Clywedog in the expected timeframe would adversely affect our future business and financial performance and the value of our stockholders investment following the Combinations.
Our shareholders and Clywedog s stockholders may not realize a benefit from the Contemplated Transactions commensurate with the ownership dilution they will experience in connection with the Contemplated Transactions.
+7 more — sign up free →
REMOVED
Our product candidates may cause serious adverse events, serious side effects or have other properties that could halt their clinical development, prevent their marketing authorization, require expansion of the trial size, limit their commercial potential or result in significant negative consequences.
We are also evaluating two product candidates to treat infectious diseases and cancer that harness our proprietary viral vector platform technologies, consisting of ChAdOx and MVA; these technologies are designed to increase disease-specific CD8+ T cells.
These include: VTP-300, a Phase 2 immunotherapeutic treatment modality that is a component of a treatment regimen to establish functional cure in patients who are chronically infected by the hepatitis B virus, and VTP-850, a second-generation immunotherapeutic candidate for the prevention of recurrence of prostate cancer.
VTP-850 is being tested in patients in a Phase 1 clinical trial in prostate cancer after surgical resection.
We intend to progress the development of these product candidates by completing the ongoing clinical trials, and seek a partner or collaborator for continuing development.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →